Review Decision – October 2015
Review of NICE Technology Appraisal Guidance No. 266; Mannitol dry powder for inhalation for treating cystic fibrosis, and No. 276; Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis
The Institute was proposing that the guidance should be incorporated into an ongoing clinical guideline and the guidance moved to the static list.
After consideration of all of the comments received during the Review Consultation, the Technology Appraisals programme has decided to proceed with this proposal.
Consequently, TA266 and TA276 will move to the static list and recommendations will be incorporated, verbatim, into the forthcoming clinical guideline for the diagnosis and management of cystic fibrosis, which is anticipated to be published in August 2017.
This page was last updated: